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ABSTRACT
Background: This study examined the use of low doses of antipsychotic medications (300 mg/day CPZeq or
less) in older Asian patients with schizophrenia and its demographic and clinical correlates.
Methods: Information on hospitalized patients with schizophrenia, aged 55 years or older, was extracted from
the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (2001–2009). Data on
1,452 patients in eight Asian countries and territories including China, Hong Kong, Japan, Korea, Singapore,
Taiwan, India, and Malaysia were analyzed. Sociodemographic and clinical characteristics and antipsychotic
prescriptions were recorded using a standardized protocol and data collection procedure.
Results:The prescription frequency for low doses of antipsychotic medications was 40.9% in the pooled sample.
Multiple logistic regression analysis of the whole sample showed that patients on low doses of antipsychotic
medications were more likely to be female, have an older age, a shorter length of illness, and less positive
symptoms. Of patients in the six countries and territories that participated in all the surveys between 2001
and 2009, those in Japan were less likely to receive low doses of antipsychotics.
Conclusion: Low doses of antipsychotic medications were only applied in less than half of older Asian patients
with schizophrenia.
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Introduction
In the past decades, following the general
improvement of mental healthcare and introduction
of effective antipsychotics into clinical practice,
many schizophrenia patients live into older
adulthood (Kohen et al., 2010). Given the higher
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likelihood of drug-induced side effects and poor
general health in older compared to younger
patients (Meyers and Jeste, 2010), rational use of
antipsychotics in this population has been gaining
increasing attention.
Neuroimaging studies demonstrate that
dopamine-2 occupancy, one of the principal
targets of antipsychotics, decreases 5%–10%
per decade with age, incurring the likelihood of
greater susceptibility for antipsychotic-induced
adverse effects (Uchida et al., 2009a). In addition,
age-related pharmacokinetic changes affect
drug absorption and excretion, which may also
exacerbate adverse effects (Masand, 2000).
Therefore, expert consensus guidelines suggest the
use of lower doses of antipsychotics in older patients
(Alexopoulos et al., 2004); for example, whereas
the recommended therapeutic dose of risperidone
is 4–8 mg for younger adult schizophrenia patients,
expert consensus guidelines suggest a range of
only 1.25–3.5 mg for older patients (Alexopoulos
et al., 2004). To date, however, no large-scale,
pharmaco-epidemiological surveys on patterns
of antipsychotic dosing in older patients with
schizophrenia have been reported in Asia.
In order to rationalize the use of psychotropic
medications in Asian countries, a large-scale long-
itudinal, observational pharmaco-epidemiological
study titled Research on Asian Psychotropic
Prescription Pattern (REAP) was initiated in 1999
in six Asian countries and territories including
China, Hong Kong, Japan, Korea, Singapore, and
Taiwan, and investigated prescription trends for
psychotropic medications in hospitalized patients
with schizophrenia in Asia.
This study is a secondary analysis of the data of
the REAP project which aimed to (1) examine the
prescribing pattern of low doses of antipsychotics
(defined as 300 mg/day chlorpromazine equivalent
(CPZeq) or less) (Sim et al., 2009) in older
Asian patients with schizophrenia during the period
between 2001 and 2009, and (2) survey its
demographic and clinical correlates. Due to the
poorer general health status of older patients and
heightened vulnerability to psychotropic-induced
side effects (Uchida et al., 2009b; Meyers and Jeste,
2010), we hypothesized that the majority of older
patients with schizophrenia would be prescribed low
doses of antipsychotics in the REAP project.
Methods
Settings, study design, and subjects
The first survey of the REAP project was carried
out in July 2001 followed by investigations in
July 2004 and October 2008 to March 2009 with
Table 1. Commonly used antipsychotic medications
and their chlorpromazine equivalent (CPZeq) in
milligrams per day (APA, 1997; Kane et al., 1998;
Woods, 2003)
ANTIPSYCHOTICS
CPZeq
(mg/day)
.....................................................................................................................................................
First-generation antipsychotic medications
Chlorpromazine 100
Haloperidol 2
Levomepromazine 100
Sulpiride 200
Trifluoperazine 5
Second-generation antipsychotic medications
Risperidone 2
Clozapine 50
Olanzapine 5
Quetiapine 75
Zotepine 66
the same study design and standardized protocol.
Centers in India, Malaysia, and Thailand joined
the surveys in 2009. Details of the REAP project
have been described elsewhere (Chong et al., 2004;
Sim et al., 2004; Shinfuku and Tan, 2008) and
are summarized as follows. Data of patients were
analyzed in this study if they satisfied the following
criteria: (1) ICD-10 or DSM-IV schizophrenia, (2)
aged 55 years or older, and (3) willingness to provide
written or oral consent in case the consent was not
waived according to the requirements of the Clinical
Research Ethics Committee in the respective study
sites. Patients with significant medical conditions
were excluded. Doses of antipsychotic drugs were
converted into CPZeq milligrams (APA, 1997;
Kane et al., 1998; Woods, 2003) (see Table 1).
Following an earlier study (Sim et al., 2009), a low
dose of antipsychotics was defined as 300 mg/day
CPZeq or less.
Eligible patients were recruited consecutively
and their sociodemographic and clinical character-
istics including age, sex, length of illness, type, and
doses of antipsychotic medications, the presence
or absence of significant psychotic symptoms in
the past month, extrapyramidal side effects (EPS)
and tardive dyskinesia (TD) were collected by a
review of medical records in 2001, and by either
a review of medical records only or a review
of medical records supplemented by a patient
interview in 2004 and 2009 using a questionnaire
designed for the study. The data were collected by
the attending psychiatrists or by members of the
research team with the agreement of the patient’s
treating psychiatrist.
The study was approved by the Clinical Research
Ethics Committees of the respective centers. Given
the anonymous nature of this observational study
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and minimal risk to patients, the patients’ informed
consent was exempted in some participating study
sites according to the requirements of the local
Clinical Research Ethics Committee (Shinfuku and
Tan, 2008). The requirements of the Clinical
Research Ethics Committee usually vary on a local
basis.
Statistical analysis
The data were analyzed using SPSS 13.0 for
Windows (SPSS, Inc., Chicago, IL). Comparisons
of low doses of antipsychotics across the three
surveys were made with χ2 tests. Multiple logistic
regression analysis was used to determine the
demographic and clinical variables influencing the
receipt of low doses of antipsychotics in the pooled
sample. Cross-sectional low dose of antipsychotics
was the dependent variable, while independent
variables included study site and survey time point,
age, gender, symptom severity, length of illness, the
presence of EPS and TD, and use of antipsychotics.
The level of significance was set at 0.05 (two-tailed).
Results
Thirty-one psychiatric institutions were involved in
2001, 25 in 2004, and 50 in 2009. A total of 1,452
patients met the study inclusion criteria; 490 in
2001, 446 in 2004, and 516 in 2009. A total of
594 patients of the 1,452 received low doses of
antipsychotics (40.9%) in the three REAP surveys;
203 in 2001 (41.4%), 192 in 2004 (43.0%), and
199 in 2009 (38.6%). There was no significant
difference across the three surveys in the use of low
doses of antipsychotics (χ2 = 2.1, df = 2, p = 0.4).
Of the patients on first-generation antipsychotics
(FGAs) only (n = 561), 229 (40.8%) received
low doses of antipsychotics; in patients on second-
generation antipsychotics (SGAs) only (n = 514)
56.2% (n = 289) received them. In contrast, only
55 (15.6%) of those prescribed combinations of
FGAs and SGAs (n = 353) received doses less than
300 CPZeq. Table 2 shows the sociodemographic
and clinical characteristics of the whole sample
and separately for patients by study site. Figure 1
presents the use of low doses of antipsychotics in
participating countries and regions over the study
period.
Table 3 displays the factors that were independ-
ently associated with low doses of antipsychotics.
Patients on low doses of antipsychotics were more
likely to be female, have an older age, a shorter
length of illness, and less positive symptoms. Of
patients in the six countries and territories that
participated in the three surveys, those in Japan were
less likely to receive low doses of antipsychotics.
Discussion
Treatment recommendation in the USA suggests
that maintenance doses of antipsychotics below
300 mg/day CPZeq usually increase the risk of
relapse (Lehman et al., 2004). Based on the
currently prevailing view, however, Asian patients
require lower doses of antipsychotics and they
are more sensitive to EPS than their Western
counterparts (Chiu et al., 1991; Frackiewicz et al.,
1997). For example, Chow et al. (1999) reported
that schizophrenia patients could be maintained
on a median daily dose of 300 mg CPZeq
of antipsychotic medications in Hong Kong. In
another study, Okuma et al. (1981) found that a
median daily dose of 270 mg CPZeq was the usual
dose in maintenance treatment of Japanese patients
with schizophrenia. Considering that antipsychotic
level may be also affected by age-related changes
in renal excretion and hepatic metabolism in the
elderly, even lower doses of antipsychotics should
likely be considered in Asian older patients with
schizophrenia.
To the best of our knowledge, there has
been no previous international study investigating
the use of low doses of antipsychotics in older
patients with schizophrenia. The assumption that
the majority of older patients with schizophrenia
would receive low doses of antipsychotics in the
current sample was not supported. The actual
mean daily dose of antipsychotics was 556 mg
CPZeq, and only 40.9% of the patients were
given low doses of antipsychotics. Nearly half
(50.1%; 234/467) patients aged 65 or older –
the standard age definition for psychogeriatric
patients in the international literature – received
low doses of antipsychotics, a figure that also fails
to support our hypothesis. The percentage of low
antipsychotic doses was particularly small in Japan
and India, although only a very small sample from
the latter country was involved. The reasons for
these differences between countries and for the
limited use of low antipsychotic doses in older Asian
patients need to be explored in future studies.
In this study, independent correlates of low
doses of antipsychotics included being female,
being older, having a shorter length of illness,
and having less positive symptoms. There are
significant sex differences in pharmacodynamics,
pharmacokinetics, and subjective tolerability to
antipsychotic drugs (Seeman, 2010). Relatively
younger patients often present with more aggressive
and impulsive behaviors (Alexopoulos et al., 2004).
These two factors could possibly explain the
association of male sex, and relatively younger
age, with less use of low antipsychotic doses.
Refractory symptoms are more often displayed
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Table 2. Sociodemographic and clinical characteristics of older Asian patients with schizophrenia in REAP surveys 2001–2009∗
CHINA
HONG
KO NG INDIA JAPAN KO REA SINGAPORE TA IWAN MALAYSIA TOTA L
(n = 215) (n = 43) (n = 5) (n = 826) (n = 128) (n = 84) (n = 143) (n = 8) (n = 1452)
MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD MEAN SD
................................................................................................................................................................................................................................................................................................................................................................................................................................................................
Age (yrs) 59.5 5.3 62.7 6.4 57.0 2.1 64.2 6.8 59.8 4.5 60.6 4.8 60.1 5.4 58.8 3.5 62.4 6.5
CPZeq (mg/d) 431 334 404 379 508 163 636 616 577 528 429 410 394 311 331 175 556 539
N % N % N % N % N % N % N % N % N %
Length of illness (<5 years) 19 8.8 3 7.0 1 20.0 16 1.9 5 3.9 6 7.1 3 2.1 1 12.5 54 3.7
Men 114 53.0 23 53.5 3 60.0 436 52.8 54 42.2 45 53.6 81 56.6 4 50.0 760 52.3
Positive symptoms 116 54.0 25 58.1 5 100 562 68.0 90 70.3 39 46.4 93 65.0 5 62.5 935 64.4
Negative symptoms 151 70.2 28 65.1 4 80.0 597 72.3 64 50.0 34 40.5 86 60.1 1 12.5 965 66.5
EPS 32 14.9 24 55.8 1 20.0 270 32.7 38 29.7 8 9.5 56 39.2 4 50.0 433 29.8
TD 13 6.0 11 25.6 0 0 74 9.0 6 4.7 3 3.6 23 16.1 2 25.0 132 9.1
FGAs1 82 38.1 19 44.2 2 40.0 588 71.2 89 69.5 72 85.7 56 39.2 6 75.0 914 62.9
SGAs2 161 74.9 22 51.2 4 80.0 513 62.1 61 47.7 7 8.3 97 67.8 2 25.0 867 59.7
Low doses 104 48.4 22 51.2 0 0 291 35.2 49 38.3 45 53.6 78 54.5 5 62.5 594 40.9
∗ There were no older patients in Thailand
1 any use of FGAs; 2 any use of SGAs
CPZeq = chlorpromazine equivalents; EPS = extrapyramidal symptoms; TD = tardive dyskinesia; FGA = first-generation antipsychotic; SGA = second-generation antipsychotic.
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Figure 1. Percentage of older patients with schizophrenia receiving low doses of antipsychotic medications.
by hospitalized patients with a longer length of
illness, which could possibly explain the relationship
between shorter length of illness and low doses
of antipsychotics. Patients with prominent positive
symptoms were more likely to receive relatively
higher doses of antipsychotics in this study, which
might be explained by the false assumption that
higher doses can better optimize the dopamine-
2 receptor occupancy (Ji, 2005). In addition, we
found that, not surprisingly, patients who were
prescribed a combination of FGAs and SGAs were
less likely to receive a low dose of antipsychotics
relative to those prescribed monotherapy, which is
in line with an earlier finding (Barbui et al., 2006).
There are a number of limitations to this
study. First, the study targeted inpatients in
eight selected Asian countries and territories
in this huge continent with a wide variety of
sociocultural, economic, and mental healthcare
systems; therefore, the findings cannot be applied
to all schizophrenia patients in Asia. Second,
due to the cross-sectional design, the causal
relationship between use of low antipsychotic doses
and demographic and clinical variables cannot be
explored. Third, a host of important variables
likely to influence appropriate prescription, such
as the length of antipsychotic treatment prior to
the study and that of the schizophrenic illness,
the effectiveness and the benefit/risk ratio of
current prescriptions, separate examination of late-
onset schizophrenia, local prescription guidelines,
drug interactions, smoking, the type of psychiatric
facilities, and mental healthcare policies were not
evaluated. Fourth, length of the current admission
was not taken into account in this study although
it may have an impact on dosing; many clinicians
titrate slowly in older patients (“start low, go slow”),
which would influence cross-sectional evaluation
of prescribing patterns. Fifth, the conversion of
antipsychotic doses into CPZeq is not accurate,
particularly for SGAs. Using the same conversion
standard when comparing the two samples (lower
dose vs. higher dose group) in the multivariate
analysis could mitigate this limitation as it may
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1041610211002791
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 15:18:05, subject to the Cambridge Core terms of use, available at
Low doses of antipsychotics in treatment of schizophrenia 1007
Table 3. Sociodemographic and clinical correlates
associated with low antipsychotic doses in the
combined sample (n = 1,439). Multiple logistic
regression analysis with higher doses of antipsychotic
medications (more than 300 mg/day CPZeq) as the
reference group
P VA LU E O R 95% CI
........................................................................................................................................................
Age (year) < 0.001 1.1 1.06–1.1
Male sex 0.001 0.7 0.6–0.9
Length of illness 0.02 0.5 0.3–0.9
Positive symptoms 0.001 0.7 0.5–0.9
Negative symptoms 0.3 0.9 0.7–1.1
EPS 0.6 1.1 0.8–1.4
TD 0.2 1.3 0.9–2.0
SGAs 1 0.7 0.9 0.7–1.2
Study sites
China – 1.0 –
Hong Kong 0.6 0.8 0.4–1.7
Japan < 0.001 0.4 0.3–0.6
Korea 0.06 0.6 0.4–1.02
Singapore 0.9 1.0 0.6–1.8
Taiwan 0.2 1.4 0.9–2.1
Study time
2001 survey – 1.0 –
2004 survey 0.4 1.1 0.8–1.5
2009 survey 0.5 0.9 0.7–1.2
Centers in India, Malaysia, and Thailand joined the survey
in 2009; therefore, they were not included in multiple logistic
regression analysis. There was co-linearity between the use of FGA
and SGA; therefore use of FGA was not included in multiple
logistic regression analysis.
OR = odds ratio; EPS = extrapyramidal symptoms; TD = tardive
dyskinesia; SGA = second-generation antipsychotic medication.
1 any use of SGAs.
reveal relative trends in prescription practices
(Ungvari et al., 2002). Finally, psychopathology and
drug-induced side effects were not assessed using
standardized rating instruments. The limitations of
the present study are partly offset by its strengths
including the large sample size and number of
participating sites.
In conclusion, the findings of our study suggest
that low doses of antipsychotics for Asian older
patients with schizophrenia were prescribed only to
a minority of patients overall and to an even smaller
percentage of those prescribed more than one
antipsychotic, a practice with limited evidence for its
efficacy (Kreyenbuhl et al., 2010). Use of the lowest
effective dose of antipsychotics in older individuals
with schizophrenia should be encouraged in daily
clinical practice in order to maximize the safety and
tolerability of treatment in this at-risk population.
It should be noted that there are no gold-standard
treatment guidelines for the use of antipsychotic
drugs. Dose adjustment should be individualized
and patients’ clinical condition should be carefully
considered. For older patients, the old clinical
wisdom of “start low and go slow” principle is
probably still the best advice.
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